NuVasive (NASDAQ:NUVA) released its quarterly earnings data on Tuesday. The medical device company reported $0.63 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.07, Briefing.com reports. The company had revenue of $292.11 million for the quarter, compared to analysts’ expectations of $290.59 million. NuVasive had a net margin of 4.39% and a return on equity of 15.16%. The business’s revenue was up 3.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.58 EPS. NuVasive updated its FY 2019 guidance to $2.25-2.35 EPS and its FY19 guidance to $2.25-2.35 EPS.
Shares of NUVA traded down $2.00 on Friday, reaching $65.72. The company’s stock had a trading volume of 16,852 shares, compared to its average volume of 280,403. The company has a quick ratio of 1.96, a current ratio of 3.75 and a debt-to-equity ratio of 0.80. NuVasive has a twelve month low of $43.51 and a twelve month high of $72.41. The firm has a market cap of $3.11 billion, a PE ratio of 29.54, a PEG ratio of 2.21 and a beta of 1.11. The company has a fifty day moving average of $58.09.
A number of equities analysts have recently issued reports on NUVA shares. BidaskClub raised shares of NuVasive from a “sell” rating to a “hold” rating in a research report on Friday, July 19th. Cantor Fitzgerald reissued a “hold” rating and set a $61.00 price objective on shares of NuVasive in a research report on Thursday, May 2nd. Robert W. Baird cut shares of NuVasive from an “outperform” rating to a “neutral” rating and set a $66.00 price objective on the stock. in a research report on Monday. Zacks Investment Research raised shares of NuVasive from a “hold” rating to a “buy” rating and set a $59.00 price objective on the stock in a research report on Wednesday, July 10th. Finally, TheStreet raised shares of NuVasive from a “c+” rating to a “b” rating in a research report on Wednesday. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and eight have issued a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $66.14.
NuVasive, Inc, a medical device company, develops and markets minimally disruptive surgical products and procedurally integrated solutions for spine surgery. Its products focus on applications for spine fusion surgery, including ancillary products and services used to aid in the surgical procedure. The company's principal products include Maximum Access Surgery, a minimally disruptive surgical platform, which includes its software-driven nerve detection and avoidance systems, and intraoperative monitoring (IOM) services and support; MaXcess, an integrated split-blade retractor system; and various specialized implants and biologics.
Featured Story: Exchange-Traded Funds (ETFs)
Receive News & Ratings for NuVasive Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuVasive and related companies with MarketBeat.com's FREE daily email newsletter.